Pfizer will list its COVID-19 treatment Paxlovid at a price of $1,390 per five-day course when it soon hits the commercial market, the drugmaker confirmed to Axios.

Why it matters: Paxlovid’s new listed price, first reported by the Wall Street Journal, will be more than twice the $529 paid by the federal government, which until now has maintained the entire U.S. supply of the key antiviral medication.

  • PP_GIRL_
    link
    fedilink
    -399 months ago

    Here ya go. My point being is that two years ago if you criticized pharmaceutical companies as still being greedy, soulless corporations you’d be laughed at and shadow banned for daring to insult our world’s saviors.